Efikasnost i sigurnost atropina u kontroli progresije miopije: sistematski pregled i meta-analiza.
BMC ophthalmology
Sažetak istraživanja
Pozadina Učinak i sigurnost atropina na odlaganje progresije miopije je opširno proučavan, ali njegova optimalna doza je još uvijek nejasna. Stoga je svrha ove meta-analize da se sistematski procijeni sigurnost i efikasnost atropina u kontroli progresije miopije, te da se istraži odnos između doze atropina i efikasnosti kontrole progresije miopije.
Metode Ovaj rad je obavljen putem podataka pretraživanih u PubMed-u, MEDLINE-u, EMBASE-u i Cochrane Centralnom registru kontrolisanih ispitivanja. Cochrane priručnik je također korišten za procjenu kvaliteta uključenih studija. Pored toga, izvršena je meta-analiza pomoću softvera Revman5.3.
Rezultati Ukupno je uključeno 10 randomiziranih kontroliranih studija (RCT). Progresija miopije je u većoj meri ublažena u grupi koja je primala atropin nego u kontrolnoj grupi, sa MD = -0,80, 95% CI (-0,94, -0,66) tokom celog perioda posmatranja. Postojala je statistička razlika između 0,05, 0,5 i 1,0% atropina (P = 0,004). Pored toga, pokazano je manje aksijalno izduživanje, sa MD = - 0,26, 95% CI (- 0,33, - 0,18) tokom čitavog perioda posmatranja.
Zaključak Efikasnost atropina u kontroli progresije miopije zavisila je od doze. 0,05% atropina je vjerovatno bila optimalna doza.
Prikaži originalni naslov i sažetak na engleskom
Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis.
Background The effect and safety of atropine on delaying the progression of myopia has been extensively studied, but its optimal dose is still unclear. Therefore, the purpose of this meta-analysis is to systematically evaluate the safety and effectiveness of atropine in controlling the progression of myopia, and to explore the relationship between the dose of atropine and the effectiveness of controlling the progression of myopia.
Methods This work was done through the data searched from PubMed, MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. The Cochrane Handbook was also used to evaluate the quality of the included studies. In addition, a meta-analysis was performed using Revman5.3 software.
Results A total of 10 randomized controlled trials (RCTs) were included. Myopia progression was mitigated greater in the atropine treatment group than that in the control group, with MD = - 0.80, 95% CI (- 0.94, - 0.66) during the whole observation period. There was a statistical difference among 0.05, 0.5, and 1.0% atropine (P = 0.004). In addition, less axial elongation was shown, with MD = - 0.26, 95% CI (- 0.33, - 0.18) during the whole observation period.
Conclusion The effectiveness of atropine in controlling the progression of myopia was dose related. A 0.05% atropine was likely to be the optimal dose.
Izvorni podaci
- DOI
- 10.1186/s12886-020-01746-w
- PMID
- 33287746
- PMCID
- PMC7720573
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom